Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma

Key Points • B-ALL development in the setting of lenalidomide treatment for MM is a distinct primary malignancy with high incidence of TP53 mutations.• Chronic lenalidomide therapy appears to be capable of expanding rare hematopoietic cells with acquired TP53 mutations.

[1]  Christopher A. Miller,et al.  Bam-readcount - rapid generation of basepair-resolution sequence metrics , 2021, J. Open Source Softw..

[2]  Erica K. Barnell,et al.  Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia , 2021, JCO precision oncology.

[3]  J. Altman,et al.  Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome , 2020, Leukemia.

[4]  Sharon Koorse Germans,et al.  Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity. , 2020, American journal of clinical pathology.

[5]  D. Hwang,et al.  B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review , 2019, BMC Cancer.

[6]  Donna Neuberg,et al.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies , 2019, Science.

[7]  M. Mohty,et al.  Current status of autologous stem cell transplantation for multiple myeloma , 2019, Blood Cancer Journal.

[8]  A. Wei,et al.  Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. , 2019, Best practice & research. Clinical haematology.

[9]  J. Welch,et al.  TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies , 2019, Haematologica.

[10]  Obi L. Griffith,et al.  Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples , 2018, Genetics in Medicine.

[11]  A. Krishnan,et al.  Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma , 2018, Leukemia.

[12]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[13]  P. Hari,et al.  Second primary malignancy after multiple myeloma‐population trends and cause‐specific mortality , 2018, British journal of haematology.

[14]  J. Wingard,et al.  Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features , 2018, Case reports in hematology.

[15]  C. Pellat-deceunynck,et al.  Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide , 2017, Haematologica.

[16]  Larocca,et al.  Second primary malignancies in multiple myeloma: an overview and IMWG consensus. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[19]  O. Landgren,et al.  Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes , 2017, Journal of internal medicine.

[20]  R. Young,et al.  Lenalidomide and secondary acute lymphoblastic leukemia: a case series , 2017, Hematological oncology.

[21]  D. Kazandjian.  Multiple myeloma epidemiology and survival: A unique malignancy. , 2016, Seminars in oncology.

[22]  A. Kohlmann,et al.  TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. , 2014, Blood.

[23]  C. Mattocks,et al.  A SNP profiling panel for sample tracking in whole-exome sequencing studies , 2013, Genome Medicine.

[24]  L. Arenillas,et al.  Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations , 2013, British journal of haematology.

[25]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[26]  R. Foà,et al.  TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy , 2013, Haematologica.

[27]  R. García‐Muñoz,et al.  Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma , 2013, Leukemia & lymphoma.

[28]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[29]  S. Kamel‐Reid,et al.  Therapy‐related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis , 2012, Cancer.

[30]  H. Kantarjian,et al.  Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? , 2012, Haematologica.

[31]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[32]  G. Morgan,et al.  A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. , 2012, Blood.

[33]  C. Cole,et al.  COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.

[34]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[35]  Ken Chen,et al.  VarScan: variant detection in massively parallel sequencing of individual and pooled samples , 2009, Bioinform..

[36]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[37]  E. Thiel,et al.  Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. , 2008, Blood.

[38]  Terrence S. Furey,et al.  The UCSC Genome Browser Database: update 2006 , 2005, Nucleic Acids Res..

[39]  M. Calasanz,et al.  TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia , 2003, Molecular carcinogenesis.

[40]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[41]  J. Rossi,et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.

[42]  A. Miller,et al.  The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. , 1979, The New England journal of medicine.

[43]  F. Rosner,et al.  Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature. , 1974, The American journal of medicine.